We are pleased to announce that portfolio company Alveron Pharma has entered the clinical development stage by initiating its first clinical trial for OKL-1111. OKL-1111 is a new drug developed by Alveron, which reverses the action of several different types of commonly used anticoagulants (“blood thinners”). Anticoagulants are widely used to prevent thrombosis (“blood clots”) in patients at high risk (e.g. stroke, deep vein thrombosis etc.). However, as a side effect, anticoagulants may cause or worsen bleeds. When bleeds occur in patients taking anticoagulants, the anticoagulant effect often needs to be stopped quickly in order to effectively manage the bleed. OKL-1111 acts rapidly and universally to reverse the anticoagulant effect, without requiring identification of the type of anticoagulant used in a particular patient which can be difficult in many settings.
Entering the clinical development stage is an important milestone for Alveron. In this first clinical study in healthy subjects, safety and tolerability will be explored as well as initial reversal data will be gathered to confirm the preclinical findings.
Please find the press release here.